Contact
searchSearch
HMP Global
Login

CAR-T Therapies Excellence Forum Excellence Forum

CAR-T Therapies Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Dr S
Videos
Dr Shah Highlights a First in-Human Study of YTB323 for Patients With R/R DLBCL
02/11/2022
Nirav Shah, MD, highlights a first in-human study of YTB323 for the treatment of patients with R/R DLBCL, presented at ASH 2021.
Nirav Shah, MD, highlights a first in-human study of YTB323 for the treatment of patients with R/R DLBCL, presented at ASH 2021.
Nirav Shah, MD, highlights a...
02/11/2022
Oncology
Nicholas Vitanza
Videos
Dr Vitanza Discusses HER2-Specific CAR-T Therapy for Young Patients With R/R Brain, Spinal Cord Tumors
08/24/2021
Dr Vitanza shares results from the phase 1 BrainChild-01 immunotherapy clinical trial, which suggests that CAR-T therapy may be a feasible treatment option for young patients with R/R brain and CNS tumors.
Dr Vitanza shares results from the phase 1 BrainChild-01 immunotherapy clinical trial, which suggests that CAR-T therapy may be a feasible treatment option for young patients with R/R brain and CNS tumors.
Dr Vitanza shares results from...
08/24/2021
Oncology
Dr Bijal Shah
Videos
Bijal Shah, MD, Discusses the Future of KTE-X19 CAR-T Therapy for R/R B-ALL
06/24/2021
In part 2 of this video series, Dr Shah, discusses the next steps of the phase 2 ZUMA-3 study of KTE-X19 for R/R B-ALL. These data were presented at the 2021 ASCO Annual Meeting.
In part 2 of this video series, Dr Shah, discusses the next steps of the phase 2 ZUMA-3 study of KTE-X19 for R/R B-ALL. These data were presented at the 2021 ASCO Annual Meeting.
In part 2 of this video series,...
06/24/2021
Oncology
Videos
KTE-X19 CAR-T Therapy Demonstrates Clinical Benefit for R/R B-ALL
06/08/2021
In part 1 of this video series, Bijal Shah, MD, shares results from the phase 2 ZUMA-3 study of KTE-X19 for R/R B-ALL. These data were presented at the 2021 ASCO Annual Meeting.
In part 1 of this video series, Bijal Shah, MD, shares results from the phase 2 ZUMA-3 study of KTE-X19 for R/R B-ALL. These data were presented at the 2021 ASCO Annual Meeting.
In part 1 of this video series,...
06/08/2021
Oncology
Dr Usmani
Videos
BCMA-Directed CAR-T Therapy Yields Durable Responses in Heavily Pretreated R/R MM
06/08/2021
Saad Usmani, MD, shares findings from the CARTITUDE-1 study of ciltacabtagene autoleucel therapy for patients with R/R MM. These data are being presented at the 2021 ASCO Annual Meeting.
Saad Usmani, MD, shares findings from the CARTITUDE-1 study of ciltacabtagene autoleucel therapy for patients with R/R MM. These data are being presented at the 2021 ASCO Annual Meeting.
Saad Usmani, MD, shares findings...
06/08/2021
Oncology
Jennifer Brudno, MD
Videos
Jennifer Brudno, MD, Discusses Anti-CD19 CAR-T Therapy for B-Cell Lymphoma
05/20/2021
Jennifer Brudno, MD, discusses the safety and feasibility of anti-CD19 CAR-T therapy for patients with B-cell lymphoma.
Jennifer Brudno, MD, discusses the safety and feasibility of anti-CD19 CAR-T therapy for patients with B-cell lymphoma.
Jennifer Brudno, MD, discusses...
05/20/2021
Oncology
Podcasts
Nirav Shah, MD, Discusses Dual-Targeted CAR-T Therapy for NHL, CLL
05/07/2021
Dr Shah discusses his research on the use of a bi-specific anti-CD20/CD19 CAR-T therapy for patients with B-cell NHL or CLL.
Dr Shah discusses his research on the use of a bi-specific anti-CD20/CD19 CAR-T therapy for patients with B-cell NHL or CLL.
Dr Shah discusses his research...
05/07/2021
Oncology
Videos
Natalie Grover, MD, Talks Anti-CD30 CAR-T Therapy for Hodgkin Lymphoma
04/30/2021
Dr Grover discusses the background and findings of her study on anti-CD30 CAR-T therapy for patients with relapsed/refractory Hodgkin lymphoma.
Dr Grover discusses the background and findings of her study on anti-CD30 CAR-T therapy for patients with relapsed/refractory Hodgkin lymphoma.
Dr Grover discusses the...
04/30/2021
Oncology
Videos
Ivana Bozic, PhD, Discusses the Efficacy of Patient Preconditioning for CAR-T Therapy
04/27/2021
Ivana Bozic, PhD, highlights her study which evaluated the efficacy of patient preconditioning in the context of CAR T-cell therapy.
Ivana Bozic, PhD, highlights her study which evaluated the efficacy of patient preconditioning in the context of CAR T-cell therapy.
Ivana Bozic, PhD, highlights her...
04/27/2021
Oncology
Videos
Dr Hutchings Discusses Glofitamab for R/R B-Cell Lymphoma
04/20/2021
Dr Martin Hutchings discusses his study on glofitamab, a bispecific antibody, in relapsed or refractory B-cell NHL.
Dr Martin Hutchings discusses his study on glofitamab, a bispecific antibody, in relapsed or refractory B-cell NHL.
Dr Martin Hutchings discusses...
04/20/2021
Oncology

Recent News

News
Asandeutertinib Demonstrates Superior Intracranial Efficacy in EGFR-Mutated NSCLC
05/31/2026
Emily Estrada
Results from the ESAONA asandeutertinib significantly improved intracranial response rates and intracranial progression-free survival in patients with EGFR-mutated NSCLC and brain metastases.
Results from the ESAONA asandeutertinib significantly improved intracranial response rates and intracranial progression-free survival in patients with EGFR-mutated NSCLC and brain metastases.
Results from the ESAONA...
05/31/2026
Oncology
News
BREAKWATER Expands First-Line Treatment Options for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer
05/31/2026
Stephanie Holland
First-line encorafenib, cetuximab, and FOLFIRI significantly improved response rates and PFS and prolonged OS vs FOLFIRI ± bevacizumab in patients with BRAF V600E–mutant metastatic colorectal cancer, according to findings from cohort 3 of the...
First-line encorafenib, cetuximab, and FOLFIRI significantly improved response rates and PFS and prolonged OS vs FOLFIRI ± bevacizumab in patients with BRAF V600E–mutant metastatic colorectal cancer, according to findings from cohort 3 of the...
First-line encorafenib,...
05/31/2026
Oncology
News
HARMONi-6 Trial Positions Ivonescimab Plus Chemotherapy as New First-Line Standard of Care in Squamous NSCLC
05/31/2026
Emily Estrada
Results from the HARMONi-6 trial position ivonescimab plus chemotherapy as a new first-line standard-of-care for patients with squamous non-small cell lung cancer.
Results from the HARMONi-6 trial position ivonescimab plus chemotherapy as a new first-line standard-of-care for patients with squamous non-small cell lung cancer.
Results from the HARMONi-6 trial...
05/31/2026
Oncology
News
Metronomic Chemo-Immunotherapy Improves Survival in Metastatic Head and Neck Cancer
05/31/2026
Stephanie Holland
Results from a phase 3 trial showed that triple oral metronomic chemotherapy combined with ultra-low-dose nivolumab demonstrates clinical promise among patients with recurrent or metastatic head and neck squamous cell carcinoma.
Results from a phase 3 trial showed that triple oral metronomic chemotherapy combined with ultra-low-dose nivolumab demonstrates clinical promise among patients with recurrent or metastatic head and neck squamous cell carcinoma.
Results from a phase 3 trial...
05/31/2026
Oncology
News
Adding Sintilimab to Adjuvant Capecitabine Fails to Improve PFS in High-Risk Nasopharyngeal Carcinoma
05/31/2026
Stephanie Holland
Results from a randomized phase 2 trial demonstrated that adding sintilimab to adjuvant capecitabine did not significantly improve PFS in patients with locoregionally advanced nasopharyngeal carcinoma who experienced a suboptimal response to...
Results from a randomized phase 2 trial demonstrated that adding sintilimab to adjuvant capecitabine did not significantly improve PFS in patients with locoregionally advanced nasopharyngeal carcinoma who experienced a suboptimal response to...
Results from a randomized phase...
05/31/2026
Oncology
News
Talazoparib Plus Enzalutamide Reduces Risk of Radiographic Progression in HRR-Deficient Metastatic Castration-Sensitive Prostate Cancer
05/30/2026
Stephanie Holland
Results from the phase 3 TALAPRO-3 trial demonstrated that talazoparib plus enzalutamide significantly improved radiographic progression-free survival in HRR-deficient metastatic castration-sensitive prostate cancer.
Results from the phase 3 TALAPRO-3 trial demonstrated that talazoparib plus enzalutamide significantly improved radiographic progression-free survival in HRR-deficient metastatic castration-sensitive prostate cancer.
Results from the phase 3...
05/30/2026
Oncology
News
Omitting Axillary Lymph Node Dissection Appears Safe in Node-Positive Breast Cancer
05/30/2026
Stephanie Holland
Results from the phase 3 SENOMAC trial demonstrated that omitting axillary lymph node dissection following a positive sentinel lymph node biopsy appears safe in patients with early-stage breast cancer.
Results from the phase 3 SENOMAC trial demonstrated that omitting axillary lymph node dissection following a positive sentinel lymph node biopsy appears safe in patients with early-stage breast cancer.
Results from the phase 3 SENOMAC...
05/30/2026
Oncology
News
Anbenitamab Demonstrates Significant Neoadjuvant Benefit in HER2-Positive Breast Cancer
05/30/2026
Stephanie Holland
Results from a phase 3 trial demonstrated that anbenitamab plus chemotherapy significantly improved total pCR compared with standard neoadjuvant HER2-directed therapy in HER2-positive early or locally advanced breast cancer.
Results from a phase 3 trial demonstrated that anbenitamab plus chemotherapy significantly improved total pCR compared with standard neoadjuvant HER2-directed therapy in HER2-positive early or locally advanced breast cancer.
Results from a phase 3 trial...
05/30/2026
Oncology
News
Erlotinib Plus Ramucirumab Followed by Osimertinib Fails to Extend Time to Failure in EGFR-Mutated NSCLC
05/30/2026
Emily Estrada
Results from the phase 3 REVOL858R trial demonstrated that erlotinib plus ramucirumab followed by osimertinib did not improve outcomes in patients with EGFR-mutated advanced NSCLC.
Results from the phase 3 REVOL858R trial demonstrated that erlotinib plus ramucirumab followed by osimertinib did not improve outcomes in patients with EGFR-mutated advanced NSCLC.
Results from the phase 3...
05/30/2026
Oncology
News
Osimertinib Plus Chemotherapy Extends PFS in Molecularly High-Risk EGFR-Mutated NSCLC
05/30/2026
Emily Estrada
Results from the phase 2 FLAME study demonstrate that osimertinib plus chemotherapy significantly improves PFS in patients with EGFR-mutated advanced non-small cell lung cancer who remain ctDNA-positive after 3 weeks of first-line osimertinib.
Results from the phase 2 FLAME study demonstrate that osimertinib plus chemotherapy significantly improves PFS in patients with EGFR-mutated advanced non-small cell lung cancer who remain ctDNA-positive after 3 weeks of first-line osimertinib.
Results from the phase 2 FLAME...
05/30/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use